Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Retreatment With Panobinostat, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
DRKS00020561Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab, panobinostat, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Universitätsklinikum Freiburg. Started Apr 2021; status: completed.
02
Drugs
daratumumabpanobinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on DRKS00020561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020561.